AVTR

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Avantor, Inc. (AVTR). This company, which is in the Zacks Medical Services industry, shows potential for another earnings beat. This company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 5.51%. For the most recent quarter, Avantor was expected to post earnings of $0.16 per share, but it reported $0.17 per share instead, representing a surprise of 6.25%. For the previous quarter, the consensus estimate was $0.21 per share, while it actually produced $0.22 per share, a surprise of 4.76%. Thanks in part to this history, there has been a favorable change in earnings estimates for Avantor lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Avantor currently has an Earnings ESP of +1.30%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on July 29, 2026. When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's e...

Avantor, Inc. previously announced that it would release its second-quarter 2026 financial results before the U.S. market opened on Wednesday, July 29, accompanied by an earnings call and webcast for investors. A separate disclosure highlighted renewed interest from institutional investors, with several hedge funds, including Greenhaven Associates, significantly increasing their Avantor holdings, signaling growing institutional engagement with the company. With institutional investors stepping up their exposure to Avantor, we will now examine how this renewed interest shapes the company’s investment narrative. The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. To own Avantor, you need to believe its role supplying mission critical lab and bioprocessing materials can offset margin pressure, flat revenue guidance and elevated leverage. The upcoming Q2 2026 earnings release and call are the key short term catalyst, as they may update investors on competitive pricing, bioprocessing demand and cash generation. The fresh wave of institutional buying does not, by itself, materially change the immediate risk that pricing pressure and weak end markets could keep profitability under strain. The most relevant development here is Avantor’s plan to report Q2 2026 results and host its earnings call on July 29, with a webcast and replay available. For investors watching renewed hedge fund interest, this update will be the next reference point to assess whether institutional confidence aligns with the company’s actual progress on margins, organic growth and leverage, or whether recent buying has arrived ahead of clearer signs of fundamental improvement. But while renewed institutional interest may look encouraging, investors should be aware of the ongoing margin pressure risk in Avantor’s core Lab Solutions segment and... Read the full narrative on Avantor (it's free!) Avantor's narrative projects $6.9 billion revenue and $603.4 million earnings by 2029. Uncover how Avantor's forecasts yield a $9.92 fair value, a 4% downside to its current price. Some of the most optimistic analysts expect Avantor to reach about US$7.0 billion in revenue and US$421.6 million in earnings by 2029, which is far more upbeat than consensus and highlights how views on the same risks and catalysts...

RADNOR, Pa., July 1, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit News & Events in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook. Investors:[email protected] Media Inquiries:[email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-to-report-second-quarter-2026-earnings-on-wednesday-july-29-2026-302813331.html

It has been about a month since the last earnings report for CVS Health (CVS). Shares have added about 8.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is CVS Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. CVS Health Corporation delivered first-quarter 2026 adjusted earnings of $2.57 per share, up 14.2% from the year-ago quarter. The figure beat the Zacks Consensus Estimate of $2.21 by 16.38%. Total revenues rose 6.2% year over year to $100.43 billion, topping the consensus mark of $94.37 billion by 6.41%. Operating execution improved across the enterprise, while days claims payable ended the quarter at 42.9 days. CVS Posts Higher Revenues on Broad Segment Gains CVS generated revenue growth across all three operating segments in the first quarter. Health Services remained the largest contributor, with segment revenues of $48.24 billion, up 11% year over year, reflecting pharmacy drug mix and brand inflation. Health Care Benefits revenues increased 3.3% to $35.97 billion, supported by strength in the Government business. Pharmacy & Consumer Wellness revenues were essentially flat at $31.99 billion, as prescription growth and mix benefits were largely offset by regulatory-related price reductions and reimbursement pressure. CVS Health Expands Consolidated Margins on Operating Leverage CVS Health’s consolidated profitability improved as operating income rose faster than the top line. Operating income increased 38.7% year over year to $4.68 billion, supported by higher segment contributions and the absence of items recorded in the prior-year period. From a margin standpoint, gross profit (total revenues less cost of products sold and health care costs) increased to $15.62 billion from $14.40 billion a year ago. Gross margin expanded 40 basis points (bps) to 15.6%, while operating margin improved 110 bps to 4.7%. Adjusted operating income rose 12.5% to $5.15 billion. Adjusted operating margin also improved 30 bps year over year, reaching 5.1%, aided by lower operating expenses of $10.94 billion compared with $11.02 billion last year. CVS Health’s Cash Build Offsets Ongoing Debt Obligations CVS Health ended the...

A month has gone by since the last earnings report for Revvity (RVTY). Shares have added about 2% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Revvity due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts. Revvity delivered first-quarter 2026 adjusted earnings of $1.06 per share, up 5.0% year over year. The bottom line beat the Zacks Consensus Estimate of $1.02 by 3.9%. Quarterly revenues of $711.1 million increased 7.0% from the year-ago period and topped the consensus mark of $705.2 million by 0.8%. Strong performance across the portfolio helped results beat expectations, with the company reporting 3% organic revenue growth for the quarter and pointing to improving signals in key end markets. RVTY’s growth was supported by contributions from both operating segments. Life Sciences revenues totaled $361.8 million, reflecting year-over-year expansion led by demand in pharma/biotech and academic/government markets. Diagnostics revenues increased to $349.3 million, aided by strength in reproductive health. The company stated better diagnostic trends outside of China, which was partially offset by softer dynamics tied to its China Immunodiagnostics footprint. Revvity reported an adjusted operating margin of 23.6% in the quarter, down 200 basis points year over year. The company attributed the margin pressure to a combination of factors, including ongoing investments, an unfavorable product mix, and the impact of an extra week in the reporting period. Adjusted gross margin was 59.5%, down 220 basis points from the prior-year quarter’s level. Below the operating line, adjusted net interest and other expense totaled $23 million, while the adjusted tax rate was 18.3%, aiding overall adjusted profitability despite the margin contraction. Selling, general and administrative expenses totaled $253.9 million, up 1.7% year over year. Research and development expenses amounted to $57.9 million, up 8% from the year-ago quarter’s reported number. The company exited the first quarter of 2026 with cash and cash equivalents of $860.3 million compared with $919.9 million at the end of the prior quarter. RV...

A month has gone by since the last earnings report for Avantor, Inc. (AVTR). Shares have added about 13% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Avantor due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers. Avantor reported first-quarter 2026 adjusted earnings per share of 17 cents, down 26.1% from the year-ago quarter. However, the bottom line surpassed the Zacks Consensus Estimate by 6.3%. GAAP earnings per share for the quarter was 6 cents, down from 9 cents per share in the prior-year quarter. Revenues totaled $1.58 billion in the reported quarter, flat year over year. The metric beat the Zacks Consensus Estimate by 2.1%. Avantor's foreign currency translation had a positive impact of 4.1%, resulting in a 4.1% sales decline on an organic basis. Laboratory Solutions (VWR Distribution & Services) Net sales in the Laboratory Solutions segment totaled $1.15 billion in the first quarter, down 5% organically year over year. The decline was primarily driven by lower volumes amid continued softness in end markets, particularly in Europe, along with a modest impact from adverse winter weather in the United States. This figure compares with our segmental projection of $1.05 billion. Despite the year-over-year decline, management indicated that the segment is stabilizing, with performance largely in line with expectations. The VWR e-commerce platform showed encouraging trends, with improvements in traffic, conversions and revenues following recent digital upgrades and the relaunch of vwr.com. However, margins were pressured by lower volumes, pricing dynamics and higher freight costs. The company expects growth to improve gradually through 2026, with a return to positive organic growth in the second half. Bioscience Production (Bioscience & Medtech Products - BMP) The Bioscience Production segment reported net sales of $431 million, reflecting a 2% organic decline year over year. The performance exceeded management expectations, supported by strong execution in process chemicals and NuSil. This figure compares with our segmental projection of $557 million. Within the segment, process chemicals delivered double-digit organic gr...

What a brutal six months it’s been for Avantor. The stock has dropped 30.3% and now trades at $7.66, rattling many shareholders. This might have investors contemplating their next move. Is now the time to buy Avantor, or should you be careful about including it in your portfolio? Get the full breakdown from our expert analysts, it’s free. Despite the more favorable entry price, we don't have much confidence in Avantor. Here are three reasons we avoid AVTR and a stock we'd rather own. We can better understand Research Tools & Consumables companies by analyzing their organic revenue. This metric gives visibility into Avantor’s core business because it excludes one-time events such as mergers, acquisitions, and divestitures along with foreign currency fluctuations - non-fundamental factors that can manipulate the income statement. Over the last two years, Avantor’s organic revenue averaged 2.1% year-on-year declines. This performance was underwhelming and implies it may need to improve its products, pricing, or go-to-market strategy. It also suggests Avantor might have to lean into acquisitions to grow, which isn’t ideal because M&A can be expensive and risky (integrations often disrupt focus). Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite. Over the next 12 months, sell-side analysts expect Avantor’s revenue to stall. While this projection implies its newer products and services will spur better top-line performance, it is still below average for the sector. Analyzing the long-term change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions. Sadly for Avantor, its EPS declined by 4.5% annually over the last five years while its revenue was flat. This tells us the company struggled because its fixed cost base made it difficult to adjust to choppy demand. We cheer for all companies helping people live better, but in the case of Avantor, we’ll be cheering from the sidelines. Following the recent decline, the stock trades at 9.3× forward P/E (or $7.66 per share). While this valuation is optically cheap, the potential downside is huge given its shaky fun...

Avantor, Inc. AVTR reported first-quarter 2026 adjusted earnings per share (EPS) of 17 cents, down 26.1% from the year-ago quarter. However, the bottom line surpassed the Zacks Consensus Estimate by 6.3%. GAAP EPS for the quarter was 6 cents, down from 9 cents per share in the prior-year quarter. Revenues grossed $1.58 billion in the reported quarter, flat year over year. The metric beat the Zacks Consensus Estimate by 2.1%. Avantor's foreign currency translation had a positive impact of 4.1%, resulting in a 4.1% sales decline on an organic basis. Laboratory Solutions (VWR Distribution & Services) Net sales in the Laboratory Solutions segment totaled $1.15 billion in the first quarter, down 5% organically year over year. The decline was primarily driven by lower volumes amid continued softness in end markets, particularly in Europe, along with a modest impact from adverse winter weather in the United States. This figure compares to our segmental projection of $1.05 billion. Despite the year-over-year decline, management indicated that the segment is stabilizing, with performance largely in line with expectations. The VWR e-commerce platform showed encouraging trends, with improvements in traffic, conversion and revenue following recent digital upgrades and the relaunch of vwr.com. However, margins were pressured by lower volumes, pricing dynamics and higher freight costs. The company expects growth to improve gradually through 2026, with a return to positive organic growth in the second half. Bioscience Production (Bioscience & Medtech Products - BMP) The Bioscience Production segment reported net sales of $431 million, reflecting a 2% organic decline year over year. The performance exceeded management expectations, supported by strong execution in process chemicals and NuSil. This figure compares to our segmental projection of $557 million. Within the segment, process chemicals delivered double-digit organic growth, driven by improved operations and strong order trends. However, fluid handling and NuSil declined double digits due to tough prior-year comparisons, while research and specialty chemicals saw a slight decline. Management noted that normalization of customer ordering patterns in certain businesses acted as a mid-single-digit headwind to growth in the quarter. Operationally, the segment showed signs of improvement, with reduced back orders and a s...

Management attributes the Q1 performance beat to improved execution in BioScience and Medtech (BMP) segments, specifically within process chemicals and new sales. The 'Revival' initiative is driving a cultural shift toward increased accountability and data-driven performance monitoring across the global organization. VWR Distribution performance was impacted by soft market conditions in Europe and severe U.S. winter weather, yet management believes the segment reached its growth trough in Q1. A significant leadership refresh is underway, with approximately 25% of the senior leadership team replaced to bring in external expertise in operations, procurement, and digital strategy. Operational improvements are being institutionalized through 'kaizen' events and a new CapEx Council to modernize manufacturing workflows and reduce unit costs. The BMP segment's strong book-to-bill ratio of 1.1x is cited as evidence of commercial momentum and a healthy bioprocessing demand funnel. Management emphasizes that while market share was lost in the prior year, the VWR platform has stabilized through successful e-commerce upgrades and contract renewals. The company anticipates returning to positive organic revenue growth in the second half of 2026 as VWR and BMP segments move past their respective growth troughs. Q2 guidance assumes a sequential decline in BMP organic growth of more than 500 basis points due to difficult year-over-year comparisons and idiosyncratic customer ordering patterns. Management expects gradual sequential margin expansion throughout the year, driven by 'Revival' productivity gains and better fixed cost absorption. The financial outlook incorporates a $10 million to $20 million headwind from Middle East conflict-related inflationary pressures on raw materials and freight. Capital allocation remains focused on debt reduction, with a firm commitment to reducing the adjusted net leverage ratio below 3x. CFO Brent Jones is departing the company next month, with Steve Eck stepping in to lead the finance function during the transition. A task force has been established to monitor and mitigate supply chain risks and price volatility stemming from geopolitical instability in the Middle East. Free cash flow in Q1 was impacted by a 'meaningful and anticipated' headwind from customer prebates associated with large enterprise contracts. Inventory provisions and v...

Image source: The Motley Fool. Wednesday, April 29, 2026 at 8 a.m. ET Chief Executive Officer — Emmanuel Ligner Chief Financial Officer — R. Jones Incoming Chief Financial Officer — Steven Eck Emmanuel Ligner: Good morning, and thank you for joining us today. Let me begin with a few financial highlights for the quarter. First quarter results exceeded our expectations due to improved execution in BioScience and Medtech product segments, and we have reaffirmed our full year guidance. VWR Distribution and Services generated $1.15 billion of revenue in the first quarter, down 5% organically versus the prior year. This performance was in line with our expectations despite soft market condition in Europe and adverse winter weather in the U.S. I'm pleased to report that in the quarter, the VWR e-commerce platform showed green shoots of improved performance in traffic, conversion and revenue growth following multiple upgrades as part of our digital road map as well as the successful relaunch of vwr.com. Importantly, Q1 results provide evidence that the VWR segment is stabilizing with financial performance in line with our expectations. Turning to BMP. BMP revenue was $431 million in the first quarter, down 2% organically versus the previous year. This was ahead of our expectations due to better-than-expected execution from process chemicals and new sales. Brent will discuss the details in his remarks, but [indiscernible] had a heavy influence on a year-over-year growth metrics. I'm pleased to report that revival efforts are already taking hold in BMP. In Q1, we saw modest improvement in BMP operational performance and we also saw strong commercial performance given the enhanced focus with which our team are working. BMP had a book-to-bill of more than 1.1x in the quarter. Other element of the P&L, including margins were generally in line with expectations, and we generated $0.17 of adjusted EPS in the quarter ahead of our expectation. There are 3 key messages I want to convey about their first quarter. First, Revival is already having a positive impact on Avantor. Across the organization, we see a clear improvement in execution and increased accountability. Our team has a more intense focus on serving customers and we are taking a data-driven approach to user their performance. Second, improved execution has translated into improved and more stable operational perfo...

Avantor's Q1 results came in ahead of expectations with revenue of $1.581 billion, adjusted EBITDA of $219 million (13.9% margin) and adjusted EPS of $0.17; free cash flow was $25 million ($39 million excluding restructuring) and the company repaid about $105 million of debt, leaving adjusted net leverage at 3.3x. Management said the Revival program is driving improved execution — BMP outperformed with a book‑to‑bill above 1.1x and is expected to bottom in Q2, while VWR showed stabilization and e‑commerce “green shoots” after platform upgrades, plus a ~25% senior leadership refresh and Kaizen/automation initiatives underway. Avantor reaffirmed full‑year guidance and Q2 adjusted EPS of $0.19–$0.20, but warned of a $10–$20 million operating income headwind from inflation and freight pressures and reiterated debt reduction as the top capital allocation priority targeting adjusted net leverage sustainably below 3x. Interested in Avantor, Inc.? Here are five stocks we like better. Avantor (NYSE:AVTR) said first-quarter 2026 results came in ahead of internal expectations, driven by improved execution in its Bioscience & Medtech Products (BMP) segment and early progress from its “Revival” operational and commercial program. Management reaffirmed full-year guidance and said it believes the company is “turning a corner financially,” with VWR Distribution & Services stabilizing and BMP expected to bottom in the second quarter. President and CEO Emmanuel Ligner said the quarter “exceeded our expectations due to improved execution in Bioscience & Medtech Products segments, and we have reaffirmed our full year guidance.” He added that adjusted earnings per share were ahead of the company’s expectations and that results provided “evidence that the VWR segment is stabilizing.” → Palantir Is Down 30%: Noise? Or a Signal to Accumulate? EVP and CFO Brent Jones reported total first-quarter revenue of $1.581 billion, down 4% organically and flat year over year on a reported basis. Adjusted EBITDA was $219 million, for a 13.9% margin, and adjusted EPS was $0.17. Free cash flow was $25 million, or $39 million excluding restructuring costs. Jones said cash flow was within expectations and reflected an anticipated headwind from customer “prebates.” Avantor repaid about $105 million of debt during the quarter and ended with an adjusted net leverage ratio of 3.3x adjusted EBITDA. Jon...

Avantor Inc. (NYSE:AVTR) reported first-quarter results on Wednesday that came in ahead of analyst expectations, sending its shares up 9.54% in premarket trading. The company posted adjusted earnings per share of $0.17, slightly above the consensus estimate of $0.16. Revenue totaled $1.58 billion, beating forecasts of $1.54 billion. Despite the beat, revenue was flat compared with the first quarter of 2025, with organic sales declining 4.1% after accounting for a positive 4.1% foreign exchange impact. “First quarter results exceeded our expectations due to improved execution in Bioscience and Medtech Products, and we saw stabilization in VWR,” said Emmanuel Ligner. “Revival is already having a positive impact, and I am encouraged by the momentum and positive energy across the organization.” Net income fell to $43.3 million from $64.5 million in the prior-year period, while adjusted EBITDA reached $219.4 million, representing a margin of 13.9%. Diluted GAAP earnings per share came in at $0.06, down from $0.09 a year earlier. The VWR Distribution & Services segment reported net sales of $1.15 billion, down 0.4% on a reported basis and 4.8% organically. Meanwhile, the Bioscience & Medtech Products segment generated $431.4 million in net sales, up 1.2% on a reported basis but down 2.0% organically. Operating cash flow totaled $58.7 million, with free cash flow of $25.2 million. Adjusted net leverage stood at 3.3x as of March 31, 2026. Avantor reaffirmed its full-year 2026 guidance previously issued during its fourth-quarter 2025 earnings call on February 11, 2026. Avantor stock price